

Clinical Policy: Darbepoetin Alfa (Aranesp)

Reference Number: IL.PHAR.236

Effective Date: 4.7.2020

Last Review Date: 5.6.24

Line of Business: Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Darbepoetin alfa (Aranesp[®]) is an erythropoiesis-stimulating agent (ESA).

FDA Approved Indication(s)

Aranesp is indicated for the treatment of:

- Anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.
- Anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.

Limitation(s) of use: Aranesp has not been shown to improve quality of life, fatigue, or patient well-being. Aranesp is not indicated for use:

- In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy.
- In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
- In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion.
- As a substitute for red blood cell transfusions in patients who require immediate correction of anemia.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Aranesp is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Anemia due to Chronic Kidney Disease (must meet all):

1. Diagnosis of anemia of CKD (dialysis and non-dialysis members);
2. Prescribed by or in consultation with a hematologist or nephrologist;
3. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation $\geq 20\%$;

4. Pretreatment hemoglobin level < 10 g/dL;
5. Failure of Epogen and Procrit, unless contraindicated or clinically significant adverse effects are experienced.

Approval duration:

Medicaid – 6 months

B. Anemia due to Chemotherapy in Patients with Cancer (must meet all):

1. Request is for use in solid or non-myeloid malignancies;
2. Members receiving myelosuppressive chemotherapy without curative intent;
3. Prescribed by or in consultation with a hematologist or oncologist;
4. Age \geq 18 years;
5. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level \geq 100 mcg/L or serum transferrin saturation \geq 20%;
6. Pretreatment hemoglobin < 10 g/dL;
6. Failure of Epogen and Procrit, unless contraindicated or clinically significant adverse effects are experienced.

Approval duration:

Medicaid – 6 months or until the completion of chemotherapy course (whichever is less)

C. Anemia Associated with Myelodysplastic Syndrome (off-label) (must meet all):

1. Diagnosis of anemia from myelodysplastic syndrome (MDS);
2. Prescribed by or in consultation with a hematologist or oncologist;
3. Age \geq 18 years;
4. One of the following (a or b):
 - a. Current (within the last 3 months) serum erythropoietin (EPO) \leq 500 mU/mL;
 - b. Member has lower risk (IPSS low/intermediate-1) disease associated with symptomatic anemia with del(5q);
5. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level \geq 100 mcg/L or serum transferrin saturation \geq 20%;
6. Pretreatment hemoglobin < 10 g/dL;
7. Failure of Epogen and Procrit, unless contraindicated or clinically significant adverse effects are experienced.

Approval duration:

Medicaid – 6 months

D. Myelofibrosis-Associated Anemia (off-label) (must meet all):

1. Diagnosis of anemia associated with myelofibrosis;
2. Prescribed by or in consultation with a hematologist or oncologist;
3. Age \geq 18 years;
4. Current (within the last 3 months) serum EPO < 500 mU/mL;
5. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level \geq 100 mcg/L or serum transferrin saturation \geq 20%;
6. Pretreatment hemoglobin < 10 g/dL;

7. Failure of Epogen and Procrit, unless contraindicated or clinically significant adverse effects are experienced.

Approval duration:

Medicaid – 6 months

E. Other diagnoses/indications (must meet all):

1. Member meets one of the following (a or b):
 - a. One of the following (i or ii):
 - i. Failure of Epogen and Procrit, unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization may be required for Epogen and Procrit*
 - ii. If Epogen and Procrit are unavailable due to shortage, failure of Retacrit, unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization may be required for Retacrit*
 - b. Request is for treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (see *Appendix D*);
2. Member meets one of the following (a or b):
 - a. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (i or ii):
 - i. For drugs on the PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.PMN.255 for Medicaid; or
 - ii. For drugs NOT on the PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.PMN.16 for Medicaid; or
 - b. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Anemia due to Chronic Kidney Disease (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;
3. One of the following (a or b):
 - a. Failure of Epogen and Procrit, unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization may be required for Epogen and Procrit*
 - b. If Procrit and Epogen are unavailable due to shortage, failure of Retacrit, unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization may be required for Retacrit*
4. Current hemoglobin \leq 12 g/dL;

5. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation $\geq 20\%$.

Approval duration:

Medicaid – 6 months

B. Anemia due to Chemotherapy in Patients with Cancer (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member meets one of the following (a or b):
 - a. One of the following (i or ii):
 - i. Failure of Epogen and Procrit, unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization may be required for Procrit and Epogen*
 - ii. If Epogen and Procrit are unavailable due to shortage, failure of Retacrit, unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization may be required for Epogen*
 - b. Request is for treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (*see Appendix D*);
3. Continuation of ESA therapy is concurrent with myelosuppressive chemotherapy;
4. If member has received ≥ 8 weeks of ESA therapy, member meets both of the following (a and b):
 - a. Documented response to therapy as evidenced by a rise in hemoglobin levels > 1 g/dL;
 - b. No RBC transfusions are required;
5. Current hemoglobin < 10 g/dL;
6. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation $\geq 20\%$.

Approval duration:

Medicaid – 6 months or until the completion of chemotherapy course (whichever is less)

C. Anemia Associated with Myelodysplastic Syndrome (off-label) (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member meets one of the following (a or b):
 - a. One of the following (i or ii):

- i. Failure of Epogen and Procrit, unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization may be required for Epogen and Procrit*
 - ii. If Epogen and Procrit are unavailable due to shortage, failure of Retacrit, unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization may be required for Epogen and Procrit*
 - b. Request is for treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (see *Appendix D*);
3. Member is responding positively to therapy;
4. If member has received ≥ 8 weeks of ESA therapy, member meets one of the following (a or b):
 - a. Documented response to therapy as evidenced by a rise in hemoglobin levels > 1.5 g/dL;
 - b. Decrease of RBC transfusions requirement;
5. Current hemoglobin ≤ 12 g/dL;
6. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation $\geq 20\%$.

Approval duration:

Medicaid – 6 months

D. Myelofibrosis-Associated Anemia (off-label) (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
 2. Member is responding positively to therapy (examples may include, but are not limited to: for transfusion-independent members with a baseline hemoglobin < 10 g/dL, a ≥ 2 g/dL increase in hemoglobin; or for previously transfusion-dependent members, transitioning to become transfusion-independent);
 3. Current hemoglobin ≤ 12 g/dL;
 4. Member meets one of the following (i or ii):
 - a. One of the following (i or ii):
 - i. Failure of Epogen and Procrit, unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization may be required for Epogen and Procrit*
 - ii. If Epogen and Procrit are unavailable due to shortage, failure of Retacrit, unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization may be required for Epogen*
 - b. Request is for treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (see *Appendix D*);
4. Adequate iron stores as indicated by current (within the last 3 months) serum ferritin level ≥ 100 mcg/L or serum transferrin saturation $\geq 20\%$.

Approval duration:

Medicaid – 6 months

E. Other diagnoses/indications (must meet all):

1. Member meets one of the following (a or b):
 - a. One of the following (i or ii):
 - i. Failure of Epogen and Procrit, unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization may be required for Epogen and Procrit*
 - ii. If Epogen and Procrit are unavailable due to shortage, failure of Retacrit, unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization may be required for Retacrit*
 - b. Request is for treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (see *Appendix D*);
2. Member meets one of the following (a or b):
 - a. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (i or ii):
 - i. For drugs on the PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.PMN.255 for Medicaid; or
 - ii. For drugs NOT on the PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.PMN.16 for Medicaid; or
 - b. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

CKD: chronic kidney disease

EPO: erythropoietin

ESA: erythropoiesis-stimulating agent

FDA: Food and Drug Administration

IPSS: International Prognostic Scoring System

MDS: myelodysplastic syndrome

Appendix B: Contraindications/Boxed Warnings

- Contraindication(s): uncontrolled hypertension, pure red cell aplasia that begins after treatment with Aranesp or other erythropoietin protein drugs, serious allergic reactions
- Boxed warning(s): ESAs increase the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access and tumor progression or recurrence

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Anemia due to CKD	<p>CKD on dialysis: starting dose 0.45 mcg/kg IV or SC weekly, or 0.75 mcg/kg IV or SC every 2 weeks. IV recommended for patients on hemodialysis</p> <p>CKD not on dialysis: starting dose 0.45 mcg/kg IV or SC at 4 week intervals</p> <p>Pediatric patients with CKD: starting dose 0.45 mcg/kg IV or SC weekly; patients with CKD not on dialysis may also be initiated at 0.75 mcg/kg every 2 weeks</p>	Varies depending on indication and frequency of administration.
Anemia due to chemotherapy in patients with cancer	Starting dose: 2.25 mcg/kg SC weekly, or 500 mcg SC every 3 weeks until completion of a chemotherapy course	
Anemia associated with MDS [†]	150-300 mcg SC every other week	500 mcg every other week

[†]Off-label NCCN recommended use

VI. Product Availability

- Single-dose vials for injection: 25 mcg, 40 mcg, 60 mcg, 100 mcg, 200 mcg, 300 mcg
- Single dose prefilled syringes for injection: 10 mcg/0.4 mL, 25 mcg/0.42 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL, 100 mcg/0.5 mL, 150 mcg/0.3 mL, 200 mcg/0.4 mL, 300 mcg/0.6 mL, and 500 mcg/1 mL

VII. References

1. Aranesp Prescribing Information. Thousand Oaks, CA: Amgen Inc.; January 2019. Available at <http://www.aranesp.com/>. Accessed January 9, 2024.
2. Bohlius J, Bohlke K, Castelli R, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update: Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents. *J Clin Oncol* 37:1336-1351. Available at: <https://ascopubs.org/doi/pdf/10.1200/JCO.18.02142>. Accessed January 23, 2024.
3. Darbepoetin alfa. In: National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at www.nccn.org. Accessed January 23, 2024.
4. Myelodysplastic Syndromes (Version 1.2023). In: National Comprehensive Cancer Network Guidelines. Available at https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. Accessed January 23, 2024.
5. Myeloproliferative Neoplasms (Version 3.2022). In National Comprehensive Cancer Network Guidelines. Available at https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf. Accessed January 23, 2024
6. Hematopoietic Growth Factors (Version 1.2023). In National Comprehensive Cancer Network Guidelines. Available at

- https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf. Accessed January 23, 2024.
7. Clinical Pharmacology [database online]. Elsevier, Inc.; 2023. Available at: <https://www.clinicalkey.com/pharmacology/>. Accessed January 23, 2024.
 8. Micromedex® Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed January 23, 2024.
 9. Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Official Journal of the International Society of Nephrology – Kidney International Supplements August 2012. 2(4): 279-335
 10. Darbepoetin alfa. In: National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at www.nccn.org. Accessed February 13, 2020.
 11. Myelodysplastic Syndromes (Version 1.2020). In: National Comprehensive Cancer Network Guidelines. Available at www.nccn.org. Accessed February 13, 2020.
 12. Myeloproliferative Neoplasms (Version 3.2019). In National Comprehensive Cancer Network Guidelines. Available at www.nccn.org. Accessed February 13, 2020.
 13. Hematopoietic Growth Factors (Version 2.2020). In National Comprehensive Cancer Network Guidelines. Available at www.nccn.org. Accessed February 13, 2020.
 14. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2017. Available at: <http://www.clinicalpharmacology-ip.com/>. Accessed February 13, 2020.
 15. Micromedex® Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed February 13, 2020.

Coding Implications –

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J0881	Injection, darbepoetin alfa, 1 mcg (non-ESRD use)
J0882	Injection, darbepoetin alfa, 1 mcg (for ESRD on dialysis)

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created, adapted from CP.PHAR.236 Darbepoetin alfa (Aranesp) for migration to HFS PDL.	4.7.20	
2Q 2021 annual review – Section II Continued therapy added Failure of Epopen and Procrit, unless contraindicated or clinically significant adverse effects are experienced. References reviewed and updated	4.23.21	
2Q 2022 annual review: references reviewed and updated	4.26.22	
2Q 2023 Annual Review: 2Q 2023 annual review: per NCCN for MDS continuation of therapy modified treatment response assessment to occur after at least 8 weeks of therapy (previously this was 12	04.10.23	

Reviews, Revisions, and Approvals	Date	P&T Approval Date
weeks); per NCCN Compendium for MDS added approval pathway for lower risk (IPSS low/intermediate-1) disease associated with symptomatic anemia with del(5q); references reviewed and updated.		
2Q 2024 annual review: for anemia associated with myelofibrosis, added requirement that pretreatment hemoglobin < 10 g/dL for initial requests and current hemoglobin ≤ 12 g/dL for continuation requests; for anemia due to CKD, added requirement for continuation requests that current hemoglobin ≤ 12 g/dL; references reviewed and updated.	5.6.24	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to

recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2020 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.